Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders
EUROPEAN JOURNAL OF CANCER(2017)
关键词
erlotinib,squamous cell carcinoma,tumour,second-line,lux-lung,long-term
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要